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Abstract
Background: Pulmonary fibrosis is characterized by excessive deposition of extracellular matrix
in the interstitium resulting in respiratory failure. The role of remodeling mediators such as
metalloproteinases (MMPs) and their inhibitors (TIMPs) in the fibrogenic process remains
misunderstood. In particular, macrophage metalloelastase, also identified as MMP-12, is known to
be involved in remodeling processes under pathological conditions. However, MMP-12
involvement in pulmonary fibrosis is unknown. Here we investigated fibrotic response to bleomycin
in MMP-12 deficient mice.
Materials and methods: C57BL/6 mice, Balb/c mice and MMP-12 -/- mice with a C57BL/6
background received 0.3 mg bleomycin by intranasal administration. 14 days after, mice were
anesthetized and underwent either bronchoalveolear lavage (BAL) or lung removal. Collagen
deposition in lung tissue was determined by Sircol™ collagen assay, MMP activity in BAL fluid was
analyzed by zymography, and other mediators were quantified in BAL fluid by ELISA. Real time PCR
was performed to assess gene expression in lung removed one or 14 days after bleomycin
administration. Student t test or Mann & Whitney tests were used when appropriate for statistical
analysis.
Results: The development of pulmonary fibrosis in "fibrosis prone" (C57BL/6) mice was associated
with prominent MMP-12 expression in lung, whereas MMP-12 expression was weak in lung tissue
of "fibrosis resistant" (Balb/c) mice. MMP-12 mRNA was not detected in MMP-12 -/- mice, in
conformity with their genotype. Bleomycin elicited macrophage accumulation in BAL of MMP-12 -
/- and wild type (WT) mice, and MMP-12 deficiency had no significant effect on BAL cells
composition. Collagen content of lung was increased similarly in MMP-12 -/- and WT mice 14 days
after bleomycin administration. Bleomycin elicit a raise of TGF-β protein, MMP-2 and TIMP-1
protein and mRNA in BAL fluids and lung respectively, and no significant difference was observed
between MMP-12 -/- and WT mice considering those parameters.
Conclusion: The present study shows that MMP-12 deficiency has no significant effect on
bleomycin-induced fibrosis.
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Introduction
Extracellular matrix (ECM) remodelling is a key factor of
numerous interstitial lung diseases. Airway remodelling-
associated disorders of ECM can be illustrated by different
pathological situations including emphysema and pul-
monary fibrosis. In the first, progressive proteolytic ECM
degradation is prevailing, whereas in the latter excessive
matrix deposition occurs. Both phenomena are hypothe-
sized to result partially from an imbalance of ECM home-
ostasis and protease – antiprotease activity [1,2] which is
partially regulated by potent fibrogenic growth factors
such as TGF-β [3,4].
Metalloproteinases (MMPs) are a family of zinc-binding
endopeptidases which proteolytic activity is involved in
normal and pathological ECM turnover. MMPs activity is
regulated by their natural tissue inhibitors, TIMPs. MMPs
have been implicated in lung pathological conditions,
including fibrosis [5], emphysema [1] and asthma [6].
Matrilysin (MMP-7) was shown to have great importance
in idiopathic pulmonary fibrosis and found to be dramat-
ically involved in bleomycin-induced pulmonary fibrosis
in mice [7]. Also, gelatinase-A (MMP-2) seems to be a
good marker of tissue remodelling. It is localized in the
area of fibroproliferation and basal membrane disruption
[8] and shows intense activity in experimental models of
pulmonary fibrosis [9-11]. Hence, TIMP-1 has been
increasingly associated with pulmonary fibrosis
[8,9,12,13]. It has been suggested that abnormal altera-
tion of MMPs/TIMPs balance could lead to disruption of
lung tissue, and/or accumulation of extracellular matrix
without adequate repair, leading to impairment of lung
function [2,3,8].
Macrophage metalloelastase, also identified as MMP-12,
has been previously described as a key factor of patholog-
ical progressive proteolytic destruction of ECM. Indeed,
MMP-12 has been reported to be essential in tissue
remodelling associated with emphysema in mice exposed
to cigarette smoke [14]. In addition, an increased expres-
sion of MMP-12 in macrophages from patients with
COPD was recently reported [15]. MMP-12 has potent
ECM remodelling properties due to its specific elastolytic
activity, but may also participate to the inflammatory
process through the activation of TNF-alpha [16]. Moreo-
ver, MMP-12 presents potent direct pro-inflammatory
properties including the ability to induce neutrophil
influx, cytokine and chemokine production [17]. MMP-
12 seems to be involved in numerous models of acute
lung inflammation [16,18-20]. Although the role of
MMP-12 in animal models of emphysema is well docu-
mented, its involvement in pulmonary fibrosis remains
unclear. We therefore investigated the involvement of
MMP-12 in the development of bleomycin-induced pul-
monary fibrosis. Firstly, we investigated differential MMP-
12 expression in lungs of "fibrosis prone" (C57BL/6) mice
and in "fibrosis resistant" (Balb/c) mice [12,21] after ble-
omycin administration. Secondly, we compared the
inflammatory and fibrotic responses of MMP-12 null
mice with those of their wild type C57BL/6 littermates.
Materials and methods
Materials
Seven-week-old Balb/c and C57BL/6 male mice were pur-
chased from CERJ (Le Genest Saint Isle, France) and quar-
antined for 1 week before experiments. MMP-12 -/- mice
were obtained from Charles River laboratories following a
transfer from Washington University [22] and rederiva-
tion on C57BL/6 background. C57BL/6 mice were used as
wild type (WT) control mice. They were housed under
controlled and ethical conditions that complied with the
Interdisciplinary Principles and Guidelines for the Use of
Animals in Research, Marketing and Education, New York
Academy of Sciences' Ad Hoc Committee on Animal
Research.
The following materials were used: bleomycin sulfate
from Bellon Laboratories (Montrouge, France); gelatin,
Triton X-100, Coomassie Brilliant Blue, Tween 20 solu-
tion, and trypan blue from Sigma (St Louis, MO, USA) ;
pepsin was from Fluka (Buchs, Switzerland) ; May-Grün-
wald and Giemsa stains from RAL (Paris, France); sodium
pentobarbital from Sanofi Santé Animale (Libourne,
France); etomidate (Hypnomidate®, 2 mg/mL) from Jans-
sen-Cilag (Issy-les-Moulineaux, France); acrylamide,
sodium dodecyl sulfate (SDS), Tris, and BSA from Euro-
bio (Les Ulis, France); ELISA kits for TGF-β and TIMP-1
detection were from R&D Systems (Minneapolis, MN,
USA); isopentane from Prolabo (Fontenay-sous-Bois,
France); a low-range weight marker for SDS-PAGE from
Biorad (Munich, Germany).
Bleomycin administration
Pulmonary fibrosis was induced by intranasal (i.n.) instil-
lation, as previously described [5,22]. Each mouse was
administered 0.3 mg bleomycin dissolved in 0.9% NaCl
solution. Control mice received saline vehicle only. One
day or 14 days after i.n. administration, mice were quickly
anesthetized by an i.p. injection of sodium pentobarbital
(60 mg/kg) and underwent either bronchoalveolar lavage
(BAL) or lung removal. These samples were stored at -
80°C until further analysis.
Bronchoalveolar lavage and preparation of tissue 
homogenates
Mice were anesthetized with an i.p. administration (20
mL/kg) of sodium pentobarbital 0.6%. Bronchoalveolar
lavage (BAL) fluids were obtained by washing the airways
10 times with 0.5 mL of 0.9% NaCl solution at 37°C with
a 1 mL syringe. The BAL fluid was centrifugated (600 g for
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10 min, 4°C), and the supernatant of the first two frac-
tions (1 mL) divided into aliquots and frozen at -80°C
until analysis. The cell pellets were then pooled with the
last fractions. Total cells were counted with a Coulter Z2®
(particle counter and size distribution analyzer, Beckman
Coulter). Red blood cells were eliminated by adding 3 mL
of distilled water for 30 seconds and then 1 mL of KCl 0.6
M onto the pellets. After centrifugation (600 g for 10 min,
4°C), supernatant was eliminated and the cells were sus-
pended in 1 mL of PBS. They were then cytospun at 700
rpm for 10 minutes (Cytospin 3®, Thermo Shandon, Ltd,
Astmoor, United Kingdom) and stained with the May-
Grünwald Giemsa method. Differential cell counts of 200
cells used standard morphological criteria.
Zymographic analysis of MMPs
Since some MMPs can degrade gelatin, zymographic tech-
niques were used to detect MMPs in BAL. In non reducing
conditions and in the presence of SDS, as previously
described [23], aliquots of BAL fluid or lung homogenate
underwent electrophoresis onto a 6% acrylamide stacking
gel /10% acrylamide separating gel containing 1 mg/mL
gelatin. After electrophoresis, gels were washed twice with
2.5% Triton X-100, rinsed with water, and incubated over-
night at 37°C in 50 mM Tris, 5 mM CaCl2, 2 µM ZnCl2,
pH = 8. The gels were stained with Coomassie Brilliant
Blue in a solution of 25% ethanol-10% acetic acid in
water and rinsed in an identical solution. Gelatinase activ-
ity appeared as clear bands against blue background. We
used recombinant protein molecular weight markers (20
kDa-214 kDa) to estimate the molecular weights of the
gelatinolytic bands. Relative enzyme amounts were quan-
tified by measuring the intensity of the bands with a den-
sitometric analyzer (Bio-Profile, Vilber-Lourmat, Marne la
Vallée, France). Results were expressed as a percentage of
the band of migration of one control BAL sample loaded
onto each gel. This sample was used as an internal stand-
ard to allow further comparisons between gels.
Determination of TGF-β-1 and TIMP-1 in BAL
The amounts of total TGF-β-1 and TIMP-1 were deter-
mined with ELISA methods, performed according to the
manufacturer's recommendations. Assay sensitivity was
15 pg/mL for TGF-β-1 and 31 pg/mL for TIMP-1. As ELISA
protocol called for processing samples in 0.6N HCl before
the assay, both TGF-β-1 latent and active forms were
measured at the same time.
In vivo expression of α1(I) collagen, Mmp-12, Mmp-2, and 
Timp-1 mRNA in lungs
For quantification of α1(I) collagen, Mmp-12, Mmp-2 gene
expressions in lung tissue, mice were sacrificed fourteen
days after either bleomycin or saline administration. Fro-
zen lung samples were ground to a fine powder using a
mortar and a pestle, and homogenized in 2 mL of Trizol
reagent (Invitrogen Life technology, Paisley, UK). After
vigorous shaking, chloroform was added and the samples
were centrifuged at 12 000 g for 20 min. Total RNA was
precipitated with isopropanol, and dissolved in RNAse-
free water. RNAs were reversed-transcribed into cDNA
using SuperScript™ II (Invitrogen Life technologies, Pais-
ley, UK), following the manufacturer's protocols with the
following exceptions : 1 µg of total RNA and random hex-
amer primers (500 ng, Promega) were used in each RT
reaction. cDNA were stored at -20°C until use as template
in subsequent polymerase chain reaction. Real-time quan-
titative PCR was performed by the fluorescent dye SYBR
Green methodology, using SYBR Green PCR Master Mix
(Applied Biosystems), and the ABI Prism 7000 apparatus
(Perkin-Elmer, Foster city, CA, USA). Primers pairs for
PCR reaction were chosen with the Primers 3 software
[24], excepted for TIMP-1 which were already described in
literature [12] (Table 1). Briefly, cDNA were mixed with 8µL SYBR Green Master Mix, 300 nM of each primer, in a
final volume of 16 µL. A first step of 10 min at 95°C was
followed by 40 cycles of amplification (95°C for 15 sec
and 60°C for 60 sec). Water and RNA that had not been
subjected to the RT step were used as negative control. For
each sample, the ABI Prism 7000 software provided an
amplification curve constructed by relating the fluores-
cence signal intensity (normalized to the fluorescence of
ROX internal passive reference) to the cycle number. The
relative quantification of the steady-state of the target
mRNA levels was calculated after normalization of the
total amount of cDNA tested by an active reference, 18s.
Fluorescence data from each sample were analyzed with
the 2[-∆∆Ct] method with the mean of the saline treated
control group as the calibrator : relative copy number of
GI RNA = 2[-∆∆Ct], were ∆∆Ct = [Ct (GI) (Unknown sample)
– Ct 18s (Unknown sample)] – [(Ct (GI)(calibrator) – Ct 18s
Table 1: Genes and primers for real time PCR.
Gene Sense Primer (5' to 3') Reverse Primer (5' to 3')
18S CGCCGCTAGAGGTGAAATT TTGGCAAATGCTTTCGCTCα1(I) collagen TCCTGCTGGTGAGAAAGGAT TCCAGCAATACCCTGAGGTC
Timp-1 GTGGGAAATGCCGCAGAT GGGCATATCCACAGAGGCTTT
Mmp-2 CCAGATACCTGCACCACCTT GTTGAAGGAAACGAGCGAAG
Mmp-12 GCTAGAAGCAACTGGGCAAC ACCGCTTCATCCATCTTGAC
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(calibrator)], GI is the gene of interest, and Ct, the cycle
threshold that was defined as the cycle number at which a
significant increase in the fluorescence signal crosses an
arbitrary intensity threshold.
Collagen measurement
For quantification of collagen in lung tissue, mice were
sacrificed fourteen days after BLM administration. Lungs
were freshly removed and frozen in isopentane using liq-
uid nitrogen. Frozen lungs were ground to a fine powder
with a mortar and pestle, weighed, and homogenized in
acetic acid 0.5 M containing pepsin (2.7 U/mL) pH = 7.4.
Total soluble collagens were extracted overnight at room
temperature by using 5 mg/ml pepsin (2.7 U/mL) in 0.5
M acetic acid and measured by the Sircol™ collagen assay
(Biocolor Ltd, Newtonabbey, UK).
Expression of the results and statistical analysis
Results were expressed as means ± SEM. Normality of data
distribution was determined using the Kolmogorov-Smir-
nov normality test. The groups were compared according
to treatment and strain by using either student t test or
nonparametric Mann-Withney Rank Sum Test, when data
distribution was respectively normal or not. For each anal-
ysis, P values under 0.05 were considered to be statistically
significant, unless another range is specified.
Results
In vivo expression of MMP-12 mRNA in lung tissue of Balb/
c and C57BL/6 mice
MMP-12 mRNA expression in lung tissue was firstly inves-
tigated in Balb/c and C57BL/6 mice (figure 1). One day
after bleomycin administration, MMP-12 mRNA level was
increased in C57BL/6 mice (4 fold), but not in Balb/c
mice. At day14, bleomycin elicited a raise of MMP-12
mRNA level both in Balb/c and in C57BL/6 mice. How-
ever, the MMP-12 mRNA level was strikingly increased in
C57BL/6 in comparison to Balb/c mice (43 fold increase
versus 4.7, respectively, P < 0.05).
In vivo expression of MMP-12 mRNA in lung tissue of 
MMP-12 -/- and WT mice
MMP-12 mRNA was not detected in lung of MMP-12 -/-
mice, confirming the genotype of the mice used for the
study. In contrast, MMP-12 was detected in control WT
mice, and was increased after bleomycin administration
(50 fold increase).
Cell composition of bronchoalveolar lavage (BAL) fluids of 
MMP-12 -/- and WT mice
The total cell number as well as the absolute number of
different cell types recovered in the BAL fluids of mice
from each experimental group is reported in table 2. Ble-
omycin administration elicited a significant increase in
the total cell count in the BAL fluids in both WT mice and
in MMP-12 -/- mice. This was due to a large increase in the
number of alveolar macrophage and, in a lesser extent, to
a rise in the number of neutrophils. Eosinophils and lym-
phocytes count raised only in BAL of WT mice after bleo-
mycin administration. Although the leucocytes influx
seems to be less important in BAL of MMP-12 -/-mice than
in WT mice, no significant difference between both strains
could be observed.
Quantification of collagen deposition in lung tissue of 
MMP-12 -/- and WT mice
Collagen content of lung tissue was determined by the Sir-
col™ collagen assay following extraction of soluble colla-
gen from lung removed at day 14. Indeed, bleomycin-
induced collagen deposition and tissue fibrosis was previ-
ously shown to be effective at this stage, under similar
conditions [5,7,10]. Bleomycin elicited an increase of col-
lagen content in both WT and MMP-12 -/- mice, in a sim-
ilar extent in both groups (figure 2A). Similarly, α1(I)
collagen mRNA was induced both in WT and MMP-12 -/-
mice (figure 2B). Basal mRNA level was higher in control
WT mice than in control MMP-12 -/- mice, whereas it was
similar in mice that were received bleomycin in both
groups.
TGF-β and TIMP-1 levels in BAL fluids of MMP-12 -/- and 
WT mice
Bleomycin elicited a significant increase of TGF-β-1 pro-
tein in BAL fluids of WT and in MMP-12 -/- mice (figure
3A), in a similar extent in both groups. TIMP-1 protein
level showed a similar profile, as it was increased 14 days
after bleomycin administration in both WT and MMP-12
MMP-12 mRNA analysis by real time quantitative polymerase chain reaction (PCR) in lung of Balb/c (blank bars) and C57BL/6 ice solid bars), removed one day or 14 days afterintranas l administration of bleomycin BLM) vehicle s lin(Co t ol)Figure 1
MMP-12 mRNA analysis by real time quantitative polymerase 
chain reaction (PCR) in lung of Balb/c (blank bars) and 
C57BL/6 mice (solid bars), removed one day or 14 days after 
intranasal administration of bleomycin (BLM) or vehicle saline 
(Control). Results are presented as mean ± SEM of the ratio 
of the number RNA copies in the unknown sample in com-
parison to the calibrator. *: P < 0.05 compared to corre-
sponding control. N = 3–5.
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-/- mice (figure 3B). No difference between WT and MMP-
12 -/- was noted.
Metalloproteinase activity in BAL fluids of of MMP-12 -/- 
and WT mice
By zymography, identification of gelatinases was based on
substrate specificity and molecular weight (figure 4A).
Zymograms loaded with BAL fluid samples exhibited the
following gelatinolytic bands : pro-MMP-2 (70 kDa), and
MMP-2 (64 kDa). These gelatinolytic activities were inhib-
ited by EDTA 10 mM, indicating that corresponding
enzymes belong to MMPs family (data not shown).
Molecular weights of latent and active forms of murine
MMP-2 were similar to those described in literature
[25,26]. Administration of bleomycin induced an increase
of both latent and active forms of MMP-2 (Fig. 4A). Active
64 kDa form of MMP-2 was measured (figure 4B). No sig-
nificant difference between WT and MMP-12 -/- groups
was observed.
Mmp-2 and Timp-1 gene mRNA analysis by real time PCR 
in MMP-12 -/- and WT mice
Effects of bleomycin administration on respective mRNA
level of Mmp-2 gene and Timp-1 gene expressions were
investigated in lung by real time PCR method (figure 5).
Bleomycin induced Mmp-2 mRNA expression in both WT
and MMP-12 -/- mice (respectively 1.6 fold and 2.8 fold)
(figure 5A). Basal level was higher in WT mice compared
to MMP-12 -/-.
Timp-1 mRNA was induced by bleomycin in MMP-12 -/-
(7.3 fold), and WT (4.1 fold), (figure 5B).
Discussion
The present study showed that MMP-12 -/- mice devel-
oped pulmonary fibrosis in a similar intensity to WT mice
and the level of TIMP-1 protein and Timp-1 mRNA is sim-
ilar in both strains.
Metalloproteinases have been described to be involved in
the remodelling process and ECM turn over in several res-
piratory diseases associated with inflammation, including
pulmonary fibrosis [27]. Indeed, it has been previously
reported that a broad range MMP inhibitor, batimastat,
prevented bleomycin-induced pulmonary fibrosis in mice
[5]. In addition, several studies focussing on specific
members of MMP family have been providing informa-
tion about their relative importance in the process. In par-
ticular, the involvement of gelatinases (MMP-2 and MMP-
9) has been described in human and in in vivo experimen-
tal animal models [5,23]. However, MMP-9 null mice
were not protected from extensive collagen deposition fol-
lowing bleomycin administration, but did not develop
small airway fibrosis [28].
MMP-12, also known as macrophage metalloelastase, and
neutrophil elastase (NE) are two major elastases involved
in lung inflammation and remodelling. Moreover, NE
null mice have already been described to be resistant to
bleomycin-induced pulmonary fibrosis [29]. In contrast,
the role of MMP-12 in the development of fibrosis is rela-
tively unknown.
In a first set of experiments, we investigated MMP-12
mRNA level in lung of Balb/c and C57BL/6 after bleomy-
cin administration. Indeed, C57BL/6 mice are known to
be "fibrosis prone" strain, whereas Balb/c mice are
described as resistant to the development of pulmonary
fibrosis [12,21]. In conformity with this, the preliminary
hydroxyproline level measurement revealed that C57BL/6
mice developed important collagen accumulation 14 days
after 0.1 mg bleomycin administration, whereas no raise
of collagen level was observed in lung of Balb/c mice [9].
Here, we show that MMP-12 mRNA level in lung tissue
was increased in C57BL/6 mice at day1 and day14, whereas
a slight raise of MMP-12 mRNA was detected only at day14
in Balb/c. We confirm here that bleomycin elicits MMP-12
mRNA induction in lung tissue of WT mice, as previously
described by Swiderski et al. [27]. Moreover, as MMP-12
mRNA level is associated with strain-dependent suscepti-
bility to develop bleomycin-induced pulmonary fibrosis,
MMP-12 seems to be a relevant candidate for the determi-
nation of a pivotal proteolytic element in the develop-
ment of pulmonary fibrosis. Hence, we investigated the
effect of MMP-12 deficiency in bleomycin-induced fibro-
sis model which hitherto has not been related.
In the present study, we observed that MMP-12 -/- mice
responded to bleomycin administration by an increase of
Table 2: Total and differential cell counts of BAL fluid from MMP-12 -/- and WT mice 14 days after intranasal administration of 
bleomycin (BLM) or saline vehicle (Control). Results are presented as the mean (.103 cells) ± SEM. n: number of mice. a: P < 0.05, b: P 
< 0.01, c: P < 0.001 compared with control mice exposed to saline solution only.
Treatment Strain N Total cells Macrophages Neutrophils Eosinophils Lymphoytes
Control WT 5 579 ± 92 561 ± 79 13 ± 10 0 ± 0 6 ± 6
MMP-12 -/- 5 547 ± 92 540 ± 94 2 ± 2 0 ± 0 4 ± 4
BLM WT 8 2204 ± 284c 1783 ± 210c 285 ± 78b 55 ± 19b 81 ± 33b
MMP-12 -/- 8 1352 ± 355a 1152 ± 255a 104 ± 62b 19 ± 17 76 ± 55
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collagen content in lung tissue, which is the hallmark of
pulmonary fibrosis. This raise did not differ significantly
from observations in WT mice, suggesting that MMP-12 is
not necessary for the development of bleomycin-induced
pulmonary fibrosis. Similarly, Lanone et al. [18] observed
in IL-13-induced injury in mice that MMP-12 deficiency
did not alter subepithelial fibrosis following inducible IL-
13 transgene expression. Consistent with their genotype,
MMP-12 -/- mice did not demonstrate MMP-12 expres-
sion.
It is interesting to observe that all mRNA level in MMP-12
-/- mice are lower than in wild type under basal condi-
tions, although all mRNA were all extracted and reverse
transcribed during the same run. However, such differ-
ences are not observed at the protein level regarding either
collagen, MMP-2 nor TIMP-1, suggesting that a strong
post-traductional regulation of gene expression occurs.
MMP-12 is known to be a prominent protease produced
by activated alveolar macrophage [1,30]. We observed a
marked accumulation of macrophages in BAL of WT mice
14 days after bleomycin administration. Taken together,
these data could mean than bleomycin induces infiltra-
tion and activation of macrophages in respiratory tract,
alveolar spaces and interstitium, leading to prominent
expression of MMP-12 in lung. Therefore MMP-12 does
not seem to be implicated in the fibrosis genesis, but may
be an indicator of macrophage activation and recruitment
following bleomycin administration.
In contrast, several studies reported that MMP-12 was nec-
essary for accumulation of macrophages in the airways,
and associated with alveolar enlargement and emphyse-
matous lesions after cigarette smoke exposure [14] or
inducible IL-13 transgene expression [18]. Hence, Nénan
et al. [17] recently demonstrated that instillation of
recombinant catalytic domain of human MMP-12 to mice
induced inflammation with important and stable macro-
phage recruitment in airways. Parks and Shapiro [30] sug-
gested that MMP-12 may actually be involved in leucocyte
Levels of TGF-β-1 (A), and TIMP-1 (B) in BAL supernatant fluids, recovered from WT (blank bars) and MMP-12 -/- mice (solid bars), at ay14 after intranasal admi istration of bleo-mycin (BLM) or saline veh cle (Cont ol)Figure 3
Levels of TGF-β-1 (A), and TIMP-1 (B) in BAL supernatant 
fluids, recovered from WT (blank bars) and MMP-12 -/- mice 
(solid bars), at day14 after intranasal administration of bleo-
mycin (BLM) or saline vehicle (Control). For TGF-β-1 and 
TIMP-1, results are represented as the mean (pg/ml) ± SEM. 
** : P < 0.01 compared to corresponding control. n = 5–8.
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A : Collagen content (mg/lung) in lung from WT (blank bars) 
and MMP-12 -/- mice (solid bars), 14 days after intranasal 
administration of bleomycin (BLM) or saline vehicle (Con-
trol). B : α1 (I) collagen I mRNA analysis by real time quantita-
tive polymerase chain reaction (PCR) amplification. Results 
are presented as mean ± SEM. *: P < 0.05 compared to cor-
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recruitment and activation. Indeed, it has been shown
that proteolytically generated elastin fragments mediate
monocyte chemotaxis [31]. However, in our model, BAL
total cell count and macrophage accumulation were not
significantly altered by MMP-12 deficiency at day14. This
may suggest that, at that time point, macrophage accumu-
lation is monitored by other mediators than MMP-12.
Taken together these results suggest that bleomycin-
induced fibrosis and associated inflammation involve dif-
ferent mechanisms from MMP-12 dependent pathways.
Several hypothesis suggest that crucial components of
fibrogenic process are due to remodelling disorders
involving growth factors such as TGF-β [2] and a non
degrading microenvironment created by a "shield" of pro-
tease inhibitors, including TIMP-1 [2,8]. TGF-β has been
demonstrated to be a prominent fibrogenic mediator in
many organs, including lung [32,33]. Moreover, TGF-β
presents a pivotal situation by regulating global lung tis-
sue remodelling. Indeed, mice lacking integrin αvβ6
(integrin αvβ6 null mice) fail to activate TGF-β and
develop an age-related emphysema, which is MMP-12-
dependent [4]. MMP-12 in lung has been described to be
down regulated by TGF-β signalling pathway [3,4]. In our
experimental model of pulmonary fibrosis, TGF-β-1 pro-
tein was induced similarly in both MMP-12 -/- and WT
A. Representative gelatin zymogram of BAL supernatant fluids 14 days after intranasal administration of bleomycin (BLM) or salin  vehicle (Control) to WT and MMP-12 -/- miceFigure 4
A. Representative gelatin zymogram of BAL supernatant fluids 14 days after intranasal administration of bleomycin (BLM) or 
saline vehicle (Control) to WT and MMP-12 -/- mice. M: molecular weight marker. B : Quantification by densitometry of 64 
kDa MMP-2 gelatinase activity on zymograms of BAL fluid, performed 14 days after intranasal administration of bleomycin 
(BLM) or vehicle saline (Control), in wild type mice (WT) (blank bars) and MMP-12 -/- mice (solid bars). Results are repre-
sented as the mean ± SEM. * : P < 0.05 compared to corresponding control. N = 4–8.
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mice. In accordance with our results, Lanone et al. [18]
did not report alteration of total TGF-β in BAL fluid of
MMP-12 -/- mice after IL-13 transgene expression. Inter-
estingly, in WT mice, bleomycin elicits both MMP-12 and
TGF-β increase. Therefore further investigations are
required in order to explain why MMP-12 expression
coexists with high TGF-β level.
Growing evidence tends to establish TIMP-1 as a major
fibrogenic effector in lung. Indeed, upon fibrogenic stim-
uli, a large amount of TIMP-1 in the remodelling tissue is
supposed to participate to the creation of a non degrading
environment, leading to alteration of protease/anti-pro-
tease balance, extracellular matrix accumulation, and tis-
sue fibrosis [2,8]. Moreover, TIMP-1 has been designated
as a key factor to explain strain-dependent susceptibility
to develop fibrogenic response to transfer of active TGF-β
in lung of mice [12]. We previously observed that TIMP-1
expression and protein were importantly increased by ble-
omycin administration. We and others had previously
reported such an induction in lung of C57BL/6 mice after
bleomycin administration [5,10,13,27]. According to our
results, MMP-12 deficiency does not seem to be involved
in TIMP-1 regulation and this would be consistent with
the development of pulmonary fibrosis in MMP-12 -/-
mice.
Gelatinases MMP-9 and MMP-2 have been observed in
various lung injury models [10,18,27], and in pulmonary
fibroses in humans [8,34]. Studying the present study, we
detected pro-MMP-2 and MMP-2 activities in BAL. Here,
MMP-2 protein and mRNA levels were both increased at
day14 after bleomycin administration, in a similar extent
in MMP-12 -/- and WT mice. This result does not appear
consistent with the hypothesis that IL-13-induced MMP-2
increase was mediated at least partially by a MMP-12-
dependent pathway [18]. Therefore, even though Th2
cytokine IL-13 has been involved in bleomycin-induced
pulmonary fibrosis [35], IL-13-induced injury model
seems to follow different pathways, including different
participation of MMP-12. Moreover, IL-13-induced injury
is associated with airspace enlargement, which is not
observed in bleomycin-induced lung injury.
Conclusion
In conclusion, we demonstrated that MMP-12 does not
appear to be involved in the fibrogenic pathway of bleo-
mycin-induced lung injury. MMP-12 deficiency did not
influence the bleomycin-induced raise of neither TGF-
beta-1 nor TIMP-1 in lung, which are described as impor-
tant pro-fibrogenic effectors. Moreover, in this model,
MMP-12 deficiency has no influence on macrophages
accumulation in lung. Accordingly to the protease/anti-
protease imbalance hypothesis, accumulation of extracel-
lular matrix may be due by dysfunction of other proteases
than MMP-12.
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